PL2192907T3 - Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych - Google Patents

Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych

Info

Publication number
PL2192907T3
PL2192907T3 PL08789793T PL08789793T PL2192907T3 PL 2192907 T3 PL2192907 T3 PL 2192907T3 PL 08789793 T PL08789793 T PL 08789793T PL 08789793 T PL08789793 T PL 08789793T PL 2192907 T3 PL2192907 T3 PL 2192907T3
Authority
PL
Poland
Prior art keywords
erythropoietin
therapeutic applications
fibronectin
compositions
fibronectin compositions
Prior art date
Application number
PL08789793T
Other languages
English (en)
Polish (pl)
Inventor
Saher Hamed
Original Assignee
Remedor Biomed Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedor Biomed Ltd. filed Critical Remedor Biomed Ltd.
Publication of PL2192907T3 publication Critical patent/PL2192907T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
PL08789793T 2007-08-16 2008-08-13 Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych PL2192907T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93549707P 2007-08-16 2007-08-16
US6431108P 2008-02-27 2008-02-27
PCT/IL2008/001119 WO2009022338A2 (en) 2007-08-16 2008-08-13 Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
EP08789793.0A EP2192907B1 (en) 2007-08-16 2008-08-13 Erythropoietin and fibronectin compositions for therapeutic applications

Publications (1)

Publication Number Publication Date
PL2192907T3 true PL2192907T3 (pl) 2018-10-31

Family

ID=40351263

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08789793T PL2192907T3 (pl) 2007-08-16 2008-08-13 Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych

Country Status (5)

Country Link
US (7) US20110123481A1 (enExample)
EP (1) EP2192907B1 (enExample)
JP (1) JP5869219B2 (enExample)
PL (1) PL2192907T3 (enExample)
WO (1) WO2009022338A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5564735B2 (ja) * 2009-07-31 2014-08-06 国立大学法人 熊本大学 アクアポリン３の発現調節剤
US20120315254A1 (en) * 2010-02-23 2012-12-13 Sebana Medical Ltd. Methods and compositions for enhancing fat graft survival
WO2014160496A1 (en) * 2013-03-13 2014-10-02 Stemetrix, Inc. Skin compositions and uses
KR102240373B1 (ko) * 2013-05-07 2021-04-13 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 입자상 탈세포화 조직의 제조방법
JP7242298B2 (ja) 2015-09-04 2023-03-20 レメドー バイオメッド リミテッド 局所エリスロポエチン製剤および前記製剤を用いて創傷治癒を改善するための方法および前記製剤の美容用途
WO2017104725A1 (ja) * 2015-12-16 2017-06-22 第一三共株式会社 創傷治療剤
CN109071482A (zh) 2016-01-15 2018-12-21 汉堡大学 携有o-鼠李糖基残基的类黄酮型化合物
US20190203240A1 (en) 2016-01-15 2019-07-04 Universitaet Hamburg Methods for the production of rhamnosylated flavonoids
WO2017223245A1 (en) * 2016-06-21 2017-12-28 The Regents Of The University Of California Wound healing using braf inhibitors
EP3538065B1 (en) * 2016-11-10 2023-08-02 ASC Regenity Ltd. Cosmetic formulations for topical applications containing erythropoietin-derived molecules
JP7605576B2 (ja) * 2018-07-25 2024-12-24 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
JP2020070270A (ja) * 2018-11-01 2020-05-07 御木本製薬株式会社 フィブロネクチン遺伝子発現促進剤
CN116531306A (zh) * 2023-02-27 2023-08-04 珠海盈盛联科生物科技有限公司 含重组人纤连蛋白具有修复功效组合物、制备方法及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
DE2437090A1 (de) 1974-08-01 1976-02-19 Hoechst Ag Reinigungsmittel
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5124155A (en) 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5264214A (en) 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5073372A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5564345A (en) * 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
GB9315810D0 (en) * 1993-07-30 1993-09-15 Univ London Stabilised materials
US7112320B1 (en) * 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6458889B1 (en) * 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6007802A (en) 1996-03-27 1999-12-28 The Procter & Gamble Co. Conditioning shampoo composition
EP0992232A4 (en) * 1997-03-11 2003-01-02 Pola Chem Ind Inc TESTING METHODS OF SKIN CARE AGENTS AND EXTERNAL SKIN CARE PRODUCTS MANUFACTURING METHOD
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
CA2316015A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6194378B1 (en) * 1998-02-18 2001-02-27 The Research Foundation Of State University Of New York Fibronectin peptides-based extracellular matrix for wound healing
GB9804720D0 (en) 1998-03-05 1998-04-29 Unilever Plc Shampoo compositions
WO2000004941A1 (en) 1998-07-24 2000-02-03 Pharmacal Biotechnologies, Inc. Osseous tissue reconstruction system and method
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
WO2006120681A2 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6960173B2 (en) 2001-01-30 2005-11-01 Eilaz Babaev Ultrasound wound treatment method and device using standing waves
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US6913762B2 (en) 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US20030147825A1 (en) * 2001-06-08 2003-08-07 Chiarelli Joseph A. Personal care compostions containing inverse emulsion polymers
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US7622299B2 (en) 2002-02-22 2009-11-24 University Of Washington Bioengineered tissue substitutes
JPWO2003103703A1 (ja) 2002-06-06 2005-10-06 中外製薬株式会社 骨代謝疾患治療剤
JP5144876B2 (ja) 2002-06-20 2013-02-13 バーダー、アウグスティヌス 増殖因子を用いて、および生物学的マトリクスあるいは支持構造を用いて細胞を増殖および分化する方法およびデバイス
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE10303584A1 (de) 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
EP1601757B1 (en) 2003-02-24 2016-11-30 Marine Polymer Technologies, Inc. Cell-polymer fiber compositions and use thereof
US7459152B2 (en) 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
EP1673102A1 (en) * 2003-10-17 2006-06-28 Crucell Holland B.V. Treatment and prevention of decubitus
CA2536041A1 (en) 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
EP1550715A1 (de) 2003-12-30 2005-07-06 Bionethos Holding Gmbh Verfahren zur Regenation von Gewebe
BRPI0418326A (pt) 2003-12-30 2007-05-02 Bionethos Holding Gmbh método de regeneração de tecidos
US20050187158A1 (en) * 2004-01-22 2005-08-25 Ranby Mats G. Pharmaceutical composition
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US20060228416A1 (en) * 2005-04-06 2006-10-12 Marie-Pierre Faure Methods for modulating topical inflammatory response
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
US7312198B2 (en) * 2005-07-12 2007-12-25 Essential Skincare, Llc Protein compositions for promoting wound healing and skin regeneration
WO2007055760A2 (en) 2005-10-31 2007-05-18 Essential Skincare, Llc Protein composition for promoting wound healing and skin regeneration
WO2007087402A2 (en) 2006-01-24 2007-08-02 Brown University Cell aggregation and encapsulation device and method
EP2656832B1 (en) * 2006-05-11 2018-12-19 Regenics AS Compositions for use in wound healing
AR063621A1 (es) * 2006-11-09 2009-02-04 Alcon Res Ltd Matriz polimerica insoluble en agua para la administracion de farmacos
US7717855B2 (en) * 2006-12-06 2010-05-18 The Hospital For Sick Children System for performing remote ischemic preconditioning
EP2337544A2 (en) * 2007-04-30 2011-06-29 Living Proof, Inc. Use of matrix metalloproteinase inhibitors in skin care
WO2008157733A2 (en) 2007-06-19 2008-12-24 Baxter International Inc. Fibrin gel for controlled release of pdgf and uses thereof
EP2018835B1 (de) * 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
US20090045968A1 (en) 2007-08-16 2009-02-19 Optimal Innovations Inc. Utility Outlets Capable of Presenting Images
EP2222327B1 (de) 2007-12-28 2017-02-15 Augustinus Bader Topische anwendung und formulierung von erythropoietin für die wundheilung der haut
WO2009093240A2 (en) 2008-01-24 2009-07-30 Ademex Ltd. Erythropoietin and fibronectin compositions for bone regeneration

Also Published As

Publication number Publication date
JP5869219B2 (ja) 2016-02-24
WO2009022338A3 (en) 2010-03-04
US20140154205A1 (en) 2014-06-05
US20190192637A1 (en) 2019-06-27
JP2010536745A (ja) 2010-12-02
US20110123481A1 (en) 2011-05-26
EP2192907A4 (en) 2011-07-06
US20170056480A1 (en) 2017-03-02
WO2009022338A2 (en) 2009-02-19
US20190117740A1 (en) 2019-04-25
US20220000987A1 (en) 2022-01-06
US20160030525A1 (en) 2016-02-04
EP2192907B1 (en) 2018-04-18
EP2192907A2 (en) 2010-06-09
US10792338B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
PL2192907T3 (pl) Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych
HUS1800007I1 (hu) Gyógyászati készítmény
IL201891A0 (en) Novel pharmaceutical composition
EP2133095A4 (en) PHARMACEUTICAL COMPOSITION
EP2133094A4 (en) PHARMACEUTICAL COMPOSITION
GB0700534D0 (en) Composition
ZA200905224B (en) Pharmaceutical composition
EP2224805A4 (en) PHARMACEUTICAL COMPOSITION
EP2224915A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0717376D0 (en) Composition and manufacture thereof
IL232923A0 (en) Enhanced erythropoietin
EP2224808A4 (en) PHARMACEUTICAL COMPOSITION
GB0809912D0 (en) Novel compositions and uses thereof
GB0715428D0 (en) Compositions and uses thereof
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0701170D0 (en) Compositions and uses thereof
IL205975A0 (en) Pharmaceutical composition
GB0701171D0 (en) Compositions and uses thereof
IL205931A0 (en) Pharmaceutical composition
GB0725264D0 (en) Compositions and uses thereof
GB0725266D0 (en) Novel esters and compositions and uses thereof
IL203964A (en) Drugs of erythropoietin and fibronectin for medicinal and cosmetic uses
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
GB0909792D0 (en) Composition and uses thereof
GB0701713D0 (en) Cosmetic composition